| 創建日期 | 上市日期 | 董事長 | 總經理 |
|---|---|---|---|
| 91/01/04 | 98/12/28 | 黃韋伯 | 紀姵如 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| 0.2(Q2) | 32.08 | 1.55 | 2.47% |
| 實收資本額 | 已發行普通股 | ||
| 605,535,940 | 60,553,594 | ||
| 主要經營業務 | |||
| 單株抗體、多株抗體、蛋白質、醫療檢測儀器及檢驗試劑 | |||
| 公司網址 | |||
| abnova.com | |||
亞諾法(4133) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 34,452 | 42,019 | 15.2% | -18% | 258,525 | 274,625 | -5.9% |
| 2023/07 | 29,895 | 30,430 | -9.1% | -1.8% | 224,073 | 232,606 | -3.7% |
| 2023/06 | 32,884 | 29,174 | 2.7% | 12.7% | 194,178 | 202,176 | -4% |
| 2023/05 | 32,030 | 37,073 | -5.3% | -13.6% | 161,294 | 173,002 | -6.8% |
| 2023/04 | 33,841 | 36,697 | -8.6% | -7.8% | 129,264 | 135,929 | -4.9% |
| 2023/03 | 37,016 | 36,865 | 14.5% | 0.4% | 95,423 | 99,232 | -3.8% |
| 2023/02 | 32,338 | 27,531 | 24% | 17.5% | 58,407 | 62,367 | -6.3% |
| 2023/01 | 26,069 | 34,836 | 0.6% | -25.2% | 26,069 | 34,836 | -25.2% |
| 2022/12 | 25,920 | 32,397 | -33.6% | -20% | 411,756 | 451,487 | -8.8% |
| 2022/11 | 39,023 | 35,482 | -9.3% | 10% | 385,836 | 419,090 | -7.9% |
| 2022/10 | 43,035 | 29,002 | 47.6% | 48.4% | 346,813 | 383,608 | -9.6% |
| 2022/09 | 29,153 | 29,782 | -30.6% | -2.1% | 303,778 | 354,606 | -14.3% |
| 2022/08 | 42,019 | 34,436 | 38.1% | 22% | 274,625 | 324,825 | -15.4% |
| 2022/07 | 30,430 | 51,807 | 4.3% | -41.3% | 232,606 | 290,389 | -19.9% |
| 2022/06 | 29,174 | 44,424 | -21.3% | -34.3% | 202,176 | 238,582 | -15.3% |
| 2022/05 | 37,073 | 47,627 | 1% | -22.1% | 173,002 | 194,158 | -10.9% |
| 2022/04 | 36,697 | 32,203 | -0.4% | 13.9% | 135,929 | 146,531 | -7.2% |
| 2022/03 | 36,865 | 35,608 | 33.9% | 3.5% | 99,232 | 114,328 | -13.2% |
| 2022/02 | 27,531 | 34,687 | -21% | -20.6% | 62,367 | 78,720 | -20.8% |
| 2022/01 | 34,836 | 44,034 | 7.5% | -20.9% | 34,836 | 44,034 | -20.9% |
| 2021/12 | 32,397 | 34,254 | -8.7% | -5.4% | 451,487 | 456,449 | -1.1% |
| 2021/11 | 35,482 | 36,348 | 22.3% | -2.4% | 419,090 | 422,195 | -0.7% |
| 2021/10 | 29,002 | 48,878 | -2.6% | -40.7% | 383,608 | 385,847 | -0.6% |
| 2021/09 | 29,782 | 42,920 | -13.5% | -30.6% | 354,606 | 336,969 | 5.2% |
| 2021/08 | 34,436 | 45,825 | -33.5% | -24.9% | 324,825 | 294,049 | 10.5% |
| 2021/07 | 51,807 | 44,995 | 16.6% | 15.1% | 290,389 | 248,224 | 17% |
| 2021/06 | 44,424 | 30,459 | -6.7% | 45.8% | 238,582 | 203,229 | 17.4% |
| 2021/05 | 47,627 | 38,021 | 47.9% | 25.3% | 194,158 | 172,769 | 12.4% |
| 2021/04 | 32,203 | 34,838 | -9.6% | -7.6% | 146,531 | 134,748 | 8.7% |
| 2021/03 | 35,608 | 38,118 | 2.7% | -6.6% | 114,328 | 99,910 | 14.4% |
| 2021/02 | 34,687 | 28,196 | -21.2% | 23% | 78,720 | 61,792 | 27.4% |
| 2021/01 | 44,034 | 33,596 | 28.5% | 31.1% | 44,034 | 33,596 | 31.1% |
| 2020/12 | 34,254 | 30,617 | -5.8% | 11.9% | 456,449 | 414,158 | 10.2% |
| 2020/11 | 36,348 | 35,509 | -25.6% | 2.4% | 422,195 | 383,541 | 10.1% |
| 2020/10 | 48,878 | 37,199 | 13.9% | 31.4% | 385,847 | 348,032 | 10.9% |
| 2020/09 | 42,920 | 30,524 | -6.3% | 40.6% | 336,969 | 310,833 | 8.4% |
夠麻吉(8472) 歷年營收季增率
| 年度/季別 | 營收季增率 | 近4季營收季增率 | 年度/季別 | 營收季增率 | 近4季營收季增率 |
|---|---|---|---|---|---|
| 2023Q2 | 4.30% | 7.78% | 2020Q3 | 3.35% | -0.45% |
| 2023Q1 | -17.82% | 4.28% | 2020Q2 | 24.49% | -1.11% |
| 2022Q4 | 22.56% | 4.35% | 2020Q1 | -23.34% | -5.08% |
| 2022Q3 | 34.92% | 12.70% | 2019Q4 | -0.33% | -0.75% |
| 2022Q2 | -12.17% | -1.08% | 2019Q3 | 0.72% | 0.85% |
| 2022Q1 | -20.90% | -9.16% | 2019Q2 | 2.87% | 2.50% |
| 2021Q4 | 81.33% | -6.32% | 2019Q1 | -6.00% | -1.03% |
| 2021Q3 | -24.24% | -15.73% | 2018Q4 | 6.25% | -4.57% |
| 2021Q2 | -33.85% | -9.65% | 2018Q3 | 7.80% | -5.88% |
| 2021Q1 | -10.37% | 3.24% | 2018Q2 | -10.84% | -6.23% |
| 2020Q4 | 0.25% | -0.30% | 2018Q1 | -17.14% | -3.23% |
評論0